Literature DB >> 18650390

Molecular and cellular signatures of human vaccine adjuvants.

F Mosca1, E Tritto, A Muzzi, E Monaci, F Bagnoli, C Iavarone, D O'Hagan, R Rappuoli, E De Gregorio.   

Abstract

Oil-in-water emulsions are potent human adjuvants used for effective pandemic influenza vaccines; however, their mechanism of action is still unknown. By combining microarray and immunofluorescence analysis, we monitored the effects of the adjuvants MF59 oil-in-water emulsion, CpG, and alum in the mouse muscle. MF59 induced a time-dependent change in the expression of 891 genes, whereas CpG and alum regulated 387 and 312 genes, respectively. All adjuvants modulated a common set of 168 genes and promoted antigen-presenting cell recruitment. MF59 was the stronger inducer of cytokines, cytokine receptors, adhesion molecules involved in leukocyte migration, and antigen-presentation genes. In addition, MF59 triggered a more rapid influx of CD11b+ blood cells compared with other adjuvants. The early biomarkers selected by microarray, JunB and Ptx3, were used to identify skeletal muscle as a direct target of MF59. We propose that oil-in-water emulsions are the most efficient human vaccine adjuvants, because they induce an early and strong immunocompetent environment at the injection site by targeting muscle cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650390      PMCID: PMC2483233          DOI: 10.1073/pnas.0804699105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  TM4: a free, open-source system for microarray data management and analysis.

Authors:  A I Saeed; V Sharov; J White; J Li; W Liang; N Bhagabati; J Braisted; M Klapa; T Currier; M Thiagarajan; A Sturn; M Snuffin; A Rezantsev; D Popov; A Ryltsov; E Kostukovich; I Borisovsky; Z Liu; A Vinsavich; V Trush; J Quackenbush
Journal:  Biotechniques       Date:  2003-02       Impact factor: 1.993

Review 2.  Immunotherapeutic uses of CpG oligodeoxynucleotides.

Authors:  Dennis M Klinman
Journal:  Nat Rev Immunol       Date:  2004-04       Impact factor: 53.106

3.  Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.

Authors:  Amanda L Gavin; Kasper Hoebe; Bao Duong; Takayuki Ota; Christopher Martin; Bruce Beutler; David Nemazee
Journal:  Science       Date:  2006-12-22       Impact factor: 47.728

Review 4.  Improving vaccines by incorporating immunological coadjuvants.

Authors:  Cara K Fraser; Kerrilyn R Diener; Michael P Brown; John D Hayball
Journal:  Expert Rev Vaccines       Date:  2007-08       Impact factor: 5.217

5.  Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis.

Authors:  M Dupuis; K Denis-Mize; A LaBarbara; W Peters; I F Charo; D M McDonald; G Ott
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

6.  Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response.

Authors:  Cecilia Garlanda; Emilio Hirsch; Silvia Bozza; Antonietta Salustri; Marika De Acetis; Rachele Nota; Alessia Maccagno; Federica Riva; Barbara Bottazzi; Giuseppe Peri; Andrea Doni; Luca Vago; Marina Botto; Rita De Santis; Paolo Carminati; Gregorio Siracusa; Fiorella Altruda; Annunciata Vecchi; Luigina Romani; Alberto Mantovani
Journal:  Nature       Date:  2002-11-14       Impact factor: 49.962

7.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Authors:  K G Nicholson; A E Colegate; A Podda; I Stephenson; J Wood; E Ypma; M C Zambon
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

8.  Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid.

Authors:  N Goto; K Akama
Journal:  Microbiol Immunol       Date:  1982       Impact factor: 1.955

9.  BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data.

Authors:  Lao H Saal; Carl Troein; Johan Vallon-Christersson; Sofia Gruvberger; Ake Borg; Carsten Peterson
Journal:  Genome Biol       Date:  2002-07-15       Impact factor: 13.583

10.  Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen.

Authors:  D T O'Hagan; M Singh; J Kazzaz; M Ugozzoli; M Briones; J Donnelly; G Ott
Journal:  Vaccine       Date:  2002-09-10       Impact factor: 3.641

View more
  158 in total

1.  An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice.

Authors:  Yuk-Fai Lau; Lay-Hoon Tang; Amber W McCall; Eng-Eong Ooi; Kanta Subbarao
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

Review 2.  Inactivated influenza vaccines: recent progress and implications for the elderly.

Authors:  Valentina Parodi; Daniela de Florentiis; Mariano Martini; Filippo Ansaldi
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

3.  Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates.

Authors:  Marcin Kwissa; Helder I Nakaya; Herold Oluoch; Bali Pulendran
Journal:  Blood       Date:  2012-01-12       Impact factor: 22.113

Review 4.  Adjuvants for human vaccines.

Authors:  Carl R Alving; Kristina K Peachman; Mangala Rao; Steven G Reed
Journal:  Curr Opin Immunol       Date:  2012-04-19       Impact factor: 7.486

5.  Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.

Authors:  Adrian J Reber; Tatiana Chirkova; Jin Hyang Kim; Weiping Cao; Renata Biber; David K Shay; Suryaprakash Sambhara
Journal:  Aging Dis       Date:  2011-09-30       Impact factor: 6.745

Review 6.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

7.  A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.

Authors:  Austin Pantel; Cheolho Cheong; Durga Dandamudi; Elina Shrestha; Saurabh Mehandru; Luke Brane; Darren Ruane; Angela Teixeira; Leonia Bozzacco; Ralph M Steinman; M Paula Longhi
Journal:  Eur J Immunol       Date:  2011-12-12       Impact factor: 5.532

Review 8.  Immunobiology of influenza vaccines.

Authors:  Margarita M Gomez Lorenzo; Matthew J Fenton
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

9.  Highly immunostimulatory RNA derived from a Sendai virus defective viral genome.

Authors:  Xiomara Mercado-López; Christopher R Cotter; Won-Keun Kim; Yan Sun; Luis Muñoz; Karla Tapia; Carolina B López
Journal:  Vaccine       Date:  2013-10-05       Impact factor: 3.641

Review 10.  The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines.

Authors:  Abdulmohammad Pezeshki; Inna G Ovsyannikova; Brett A McKinney; Gregory A Poland; Richard B Kennedy
Journal:  Expert Rev Vaccines       Date:  2019-02-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.